Spruce Biosciences, Inc.
Corticotropin releasing factor receptor antagonists

Last updated:

Abstract:

The present invention provides novel pharmaceutical compositions comprising-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,- 5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Status:
Grant
Type:

Utility

Filling date:

25 Jun 2021

Issue date:

7 Jun 2022